Page 207 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
References
1. Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Ann Rev Immunol. 2015;33:787-821.
2. Lee SP, Constandinou CM, Thomas WA, et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood. 1998;92(3):1020-1030.
3. Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin’s disease. Blood. 1995;86(4):1493-1501.
4. Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120(16):3280-3287.
5. Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420-2430.
6. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/ refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-1439.
7. Taya M, Hammes SR. Glycoprotein non-metastatic melanoma protein B (GPNMB) and cancer: a novel potential therapeutic target. Steroids. 2018;133:102-107.
8. Chung JS, Sato K, Dougherty, II, Cruz PD, Jr., Ariizumi K. DC-HIL is a negative regulator of T lymphocyte activation. Blood. 2007;109(10):4320-4327.
9. Xiong A, Zhang J, Chen Y, Zhang Y, Yang F. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine. 2022;83:104239.
10. Chung JS, Tamura K, Akiyoshi H, Cruz PD, Jr., Ariizumi K. The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells. J Immunol. 2014;192(6):2576-2584.
11. Tomihari M, Chung JS, Akiyoshi H, Cruz PD, Jr., Ariizumi K. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res. 2010;70(14):5778-5787.
12. Sakano Y, Noda T, Kobayashi S, et al. Tumor endothelial cell- induced CD8(+) T-cell exhaustion via GPNMB in hepatocellular carcinoma. Cancer Sci. 2022;113(5):1625-1638.
13. Chung JS, Tamura K, Cruz PD, Jr., Ariizumi K. DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth. J Invest Dermatol. 2014;134(11):2784-2794.
14. Silva WN, Prazeres P, Paiva AE, et al. Macrophage-derived GPNMB accelerates skin healing. Exp Dermatol. 2018;27(6):630-635.
15. Ramani V, Chung JS, Ariizumi K, Cruz PD, Jr. Soluble DC-HIL/ Gpnmb modulates T-lymphocyte extravasation to inflamed skin. J Invest Dermatol. 2022;142(5):1372-1380.
16. Chung JS, Ramani V, Kobayashi M, et al. DC-HIL/Gpnmb is a negative regulator of tumor response to immune checkpoint inhibitors. Clin Cancer Res. 2020;26(6):1449-1459.
17. Cortese N, Carriero R, Barbagallo M, et al. High-resolution analysis of mononuclear phagocytes reveals GPNMB as a prognostic marker in human colorectal liver metastasis. Cancer Immunol Res. 2023;11(4):405-420.
Haematologica | 110 January 2025
199